About this episode
In this Energy Code Deep Dive, Dr. Mike Belkowski and moderator Don Bailey break down a 2024 systematic review, “Targeting Aging With Urolithin A in Humans," that focuses on human supplementation studies, not “eat pomegranate and hope.”
You’ll learn what Urolithin A is (and why your gut bacteria can make results wildly inconsistent), why it’s tied to “geroprotection,” and what the clinical evidence actually supports so far: dose-dependent anti-inflammatory signals, changes in mitochondrial/autophagy gene markers, and some improvements in strength/endurance — with a reality check on what didn’t move (ATP max, broad physical function, microbiome composition, body comp, cardiovascular markers in short windows).
Bottom line: promising, practical, but still early.
-
Article Discussed in Episode:
Targeting aging with urolithin A in humans: A systematic review
-
Key Quotes From Dr. Mike & Don:
“It’s like giving two people the same coffee beans, but one of them doesn’t own a coffee grinder!”
"It may be improving the ‘quality control and efficiency settings’ more than raw peak horsepower.“
“So it’s like tuning the car so it runs smoother; not necessarily making the top speed higher.”
"It’s not a ‘lose 20 pounds and become a triathlete’ pill.”
-
Key points
Urolithin A is a gut-derived metabolite from ellagic acid foods (pomegranate, walnuts, berries), but many people don’t convert well. So food intake ? reliable levels.
Supplementation “skips the gut lottery” and produces higher, more consistent plasma levels than food sources.
The systematic review included 5 human studies / 250 healthy participants with 10–1000 mg/day for 28 days to 4 months.
Biggest consistent theme: dose-dependent anti-inflammatory effects (some markers improve more at 1000 mg/day over 4 months).
Mitochondria story is nuanced: it may improve gene expression signatures related to mitochondrial activity, autophagy, and fatty-acid oxidation—more “quality control” than peak power.
What it didn’t reliably do: increase maximal ATP production, consistently boost biogenesis/dynamics markers, change gut microbiota composition, or meaningfully affect body metrics/cardiovascular outcomes in short trials.
Muscle outcomes: some gains in specific strength/endurance measures (e.g., torque metrics; certain fatigue tests), but not universal (e.g., handg
